# Do anti-aging peptides work? What has been tested

> Elamipretide, epitalon and MOTS-c: no human trial of any of them against ageing was found, and their lifespan data come from mice, rats and flies.

Source page: https://peptioresearch.com/articles/do-anti-aging-peptides-work/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-10
Type: Evidence review

None of these three peptides sold with ageing claims, elamipretide, epitalon and MOTS-c, has been tested against ageing, lifespan or any ageing outcome in a human trial, in the searches behind this site's pages on them. The closest is a single infusion of elamipretide in 39 older adults, which measured a muscle energy marker and found the effect gone by day 7 [1].

The lifespan data are from animals. No lifespan study of elamipretide was found in any species. For MOTS-c, the one mouse lifespan measurement was not significant over the whole survival curve (P = 0.23) [2]. For epitalon, mean lifespan did not change in female SHR mice or in rats under standard light [3] [4], was 13.5% longer (p<0.05) in one transgenic mouse model whose later reanalysis is described as pointing both ways [5] [6], and was reported 11 to 16% longer in fruit flies [7]. Every one of these studies comes from one research network, and no independent replication was found.

The only approved product among them is Forzinity, an elamipretide injection, approved in the United States to improve muscle strength in people with Barth syndrome, a rare inherited mitochondrial disease, who weigh at least 30 kg. Its own label says it was not superior to placebo on the primary endpoints of its randomised trial [8]. And the human figures that circulate online are mostly not about the product being sold: epitalon's mortality numbers come from a different substance, and MOTS-c's human data are measurements of the peptide the body makes.

## What "works" would have to mean

For a peptide to be shown to slow ageing, someone would have to measure ageing: lifespan, or the onset of age-related disease, frailty or death, in a controlled study. None of the work found does that in people. What it measures instead are surrogates, markers that are hoped to track ageing: a rate of energy production in muscle, telomere length in cultured cells, a melatonin breakdown product in urine, blood levels of a peptide. A surrogate moving is not the same as a person ageing more slowly.

In animals, lifespan can be measured, and how it is reported matters. Mean or median lifespan describes the whole group. Maximum lifespan and "the last 10% of survivors" describe only the longest-lived animals in a group.

## Elamipretide

Elamipretide, also called SS-31, is the one of the three with published randomised trials of clinical endpoints, all in diseases apart from the single-infusion study in older adults described below. Most of the published ones missed their primary endpoints: in Barth syndrome (12 patients, the randomised phase of TAZPOWER) [9], primary mitochondrial myopathy (218 adults over 24 weeks in MMPOWER-3) [10], heart failure with reduced ejection fraction (71 patients over 4 weeks) [11], heart attack [12], dry age-related macular degeneration with geographic atrophy (176 patients over 48 weeks) [13] and Leber hereditary optic neuropathy, an inherited cause of vision loss (12 patients) [14].

The one published randomised trial in older adults gave 39 people aged 60 to 85, enrolled because their muscle mitochondria were poorly functioning, a single infusion. ATPmax, the maximal rate at which muscle makes ATP, rose borderline immediately afterwards (P = 0.055 for the absolute change, P = 0.045 for the percentage change), was no different by day 7, and fatigue resistance did not change [1].

> **Evidence (Animal research).**
> The ageing claims for SS-31 rest on mice. In C57BL/6J mice treated for 8 weeks, it was reported to slow frailty accumulation without detectable changes in tissue epigenetic or transcriptomic age [15]. Studies in aged female mice over 8 months and old C57BL mice over 8 weeks reported effects on exercise tolerance and heart function [16] [17]. None measured lifespan.

## Epitalon

Epitalon is a synthetic four-amino-acid peptide. No registered human trial of it was found, and no randomised trial measuring a clinical outcome. FDA describes one study of a melatonin breakdown product as randomised and placebo-controlled, while noting it did not specify blinding and measured no sleep outcome [18]. The other reports of it being given to people are uncontrolled, come from the group that developed it, and measure surrogates [19] [20].

> **Evidence (Animal research).**
> In female outbred SHR mice, 54 per group, epitalon did not change mean lifespan; the last 10% of survivors lived 13.3% longer and maximum lifespan was 12.3% longer [3]. In female rats of unreported strain under standard light it did not change lifespan, while under natural and constant light maximum lifespan was 95 and 24 days longer [4], and in male rats it "virtually did not change the mean lifespan" [21]. In female transgenic FVB/N HER-2/neu mice, bred to develop breast tumours, a 2002 report found 13.5% longer mean lifespan (p<0.05) [5], but a 2025 review describes a later reanalysis by the same network as finding, depending on dose, either reduced maximum lifespan or better survival [6]. In Canton-S fruit flies, adult lifespan was reported 11 to 16% longer [7].

> **Limitation.**
> All of these lifespan studies come from one research network, mostly read as abstracts, and no independent replication was found.

The human mortality figures quoted for epitalon, such as deaths falling 1.6 to 1.8-fold in 266 elderly people, come from studies of epithalamin, an extract of cattle pineal gland. Epithalamin is a mixture; epitalon is one synthetic molecule. Those studies are not evidence about epitalon [22] [23].

## MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. No result from any human trial of it was found. One placebo-controlled phase 2a trial in 120 adults with prediabetes and overweight or obesity is registered as recruiting, with no results [24].

The human studies that exist measure the MOTS-c the body makes, and find associations in conflicting directions: a 2024 meta-analysis of 602 people found plasma levels lower in type 2 diabetes but higher in obesity, the obesity result significant only after overweight participants were excluded [25]. The blood test itself is in doubt. A mass spectrometry method could not confirm the ELISA-measured levels in 20 healthy people [26], and a 2024 correction by other researchers states that endogenous MOTS-c "still remains undetected" by that method [27].

The only human data on an administered peptide concern CB4211, a different molecule. In a press release filed with the SEC on 10 August 2021, its developer, CohBar, called it "a novel and improved analog of MOTS-c" and reported topline results; that is the company's own, unreviewed announcement [28]. The trial's registry record lists it as completed in April 2021 with no results posted, and no peer-reviewed publication was found [29].

> **Evidence (Animal research).**
> In male C57BL/6N mice treated from 23.5 months, the originating group reported better grip strength and walking, and "a trend towards increased median (6.4%) and maximum (7.0%) lifespan" that was not significant over the whole survival curve (P = 0.23). The authors write that "Larger cohorts will be needed" [2].

## What the surrogates are

Each of the three has a marker that stands in for an outcome nobody has measured:

- **Elamipretide:** ATPmax in muscle, measured immediately after one infusion in older adults [1].
- **Epitalon:** telomere length and telomerase activity in cultured human cells, not in people [30]. In white blood cells from 11 donors, telomeres lengthened in 5 and shortened in 2 [31]. In an independent 2025 study, telomeres also lengthened in breast cancer cell lines [32]. In people, the marker is a melatonin breakdown product in urine, 1.7 times higher in a report with no stated sample size or control group [19].
- **MOTS-c:** plasma levels of the body's own peptide, measured by an assay mass spectrometry has not confirmed [26].

No study measuring telomere length in people given epitalon was found, and no published human study testing whether taking MOTS-c does anything was found.

## What regulators say

The three sit in different places with FDA. Elamipretide is approved as Forzinity, on 19 September 2025, under accelerated approval to improve muscle strength in Barth syndrome patients weighing at least 30 kg, an approval based on what the label calls an intermediate clinical endpoint, with continued approval possibly contingent on a confirmatory trial [33] [8]. That approval covers the approved product for that indication, and says nothing about material sold under the same name.

Epitalon and MOTs-C, FDA's spelling, appear on FDA's compounding pages, both in its table of bulk drug substances nominated for compounding but withdrawn [34]. Both were nonetheless on the agenda of FDA's Pharmacy Compounding Advisory Committee in July 2026: MOTs-C on 23 July for obesity and osteoporosis, epitalon on 24 July for insomnia. No outcome was found on the meeting page, reopened on 6 November 2026 [35]. A trade journal and a law firm, both second hand, report that the committee voted to recommend both for the list, MOTS-c by 7 to 5 with two abstentions in the journal's account [36] [37]. That is advice on compounding, against FDA's own briefings, and says nothing about ageing [36]. In October 2026 HHS said it does not intend to act against compounders of epitalon acetate or MOTS-c acetate who meet ten listed conditions [38]. That is a draft, non-binding enforcement position [39], not an approval, and it says nothing about ageing either.

> **Caution.**
> FDA states that compounded drugs containing epitalon "may pose risk for immunogenicity for certain routes of administration" "due to the potential for aggregation and peptide-related impurities", and that compounded MOTs-C "may pose significant risk for immunogenicity", the risk of provoking an immune response. For both, FDA says it lacks information on whether the substance would cause harm if given to humans [34].

## Sources

1. Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. https://doi.org/10.1371/journal.pone.0253849
2. Reynolds JC, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. https://doi.org/10.1038/s41467-020-20790-0
3. Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003. https://doi.org/10.1023/a:1025114230714
4. Vinogradova IA et al. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. Bulletin of Experimental Biology and Medicine. 2007. https://doi.org/10.1007/s10517-007-0441-z
5. Anisimov VN et al. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of Experimental Biology and Medicine. 2002. https://doi.org/10.1023/a:1021104819170
6. Araj SK et al. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. https://doi.org/10.3390/ijms26062691
7. Khavinson VK et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development. 2000. https://doi.org/10.1016/s0047-6374(00)00217-7
8. FORZINITY (elamipretide) injection, prescribing information (Revised 9/2025). DailyMed, U.S. National Library of Medicine (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75
9. Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2021. https://doi.org/10.1038/s41436-020-01006-8
10. Karaa A et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. https://doi.org/10.1212/WNL.0000000000207402
11. Butler J et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure. 2020. https://doi.org/10.1016/j.cardfail.2020.02.001
12. Gibson CM et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal. 2016. https://pubmed.ncbi.nlm.nih.gov/26586786/
13. Ehlers JP et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science. 2025. https://pubmed.ncbi.nlm.nih.gov/39605874/
14. Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024. https://doi.org/10.1016/j.ophtha.2023.10.033
15. Mitchell W et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025. https://pubmed.ncbi.nlm.nih.gov/40080911/
16. Campbell MD, Samuelson AT, Chiao YA. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. GeroScience. 2023. https://pubmed.ncbi.nlm.nih.gov/36840897/
17. Chiao YA, Zhang H, Sweetwyne M. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020. https://pubmed.ncbi.nlm.nih.gov/32648542/
18. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193345/download
19. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020. https://pubmed.ncbi.nlm.nih.gov/33280326/
20. Khavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. 2002. https://pubmed.ncbi.nlm.nih.gov/12195242/
21. Vinogradova IA et al. Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of Experimental Biology and Medicine. 2008. https://doi.org/10.1007/s10517-008-0121-7
22. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003. https://pubmed.ncbi.nlm.nih.gov/14523363/
23. Korkushko OV et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine. 2006. https://doi.org/10.1007/s10517-006-0365-z
24. A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07505745
25. Zhou Q et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024. https://doi.org/10.1186/s13098-024-01405-w
26. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019. https://doi.org/10.1002/rcm.8337
27. Emser SV et al. Corrigendum: Extension of mitogenome enrichment based on single long-range PCR: mtDNAs and putative mitochondrial-derived peptides of five rodent hibernators. Frontiers in Genetics. 2024. https://doi.org/10.3389/fgene.2024.1386502
28. CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity (Form 8-K Exhibit 99.2). CohBar, Inc., filed with the U.S. Securities and Exchange Commission. 2021. https://www.sec.gov/Archives/edgar/data/1522602/000121390021041377/ea145151ex99-2_cohbar.htm
29. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. ClinicalTrials.gov. 2021. https://clinicaltrials.gov/study/NCT03998514
30. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. https://doi.org/10.1023/a:1025493705728
31. Khavinson VK et al. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. Bulletin of Experimental Biology and Medicine. 2019. https://doi.org/10.1007/s10517-019-04664-0
32. Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. https://doi.org/10.1007/s10522-025-10315-x
33. Drugs@FDA: FORZINITY (elamipretide hydrochloride), NDA 215244. U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215244
34. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
35. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
36. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
37. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
38. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
39. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf
